CERo Therapeutics Holdings, Inc.
CERO
$0.09
$0.0113.64%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.80% | 9.99% | -23.75% | 66.71% | 918.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.46% | 5.50% | 12.19% | 86.90% | 186.68% |
| Operating Income | -10.46% | -5.50% | -12.19% | -86.90% | -186.68% |
| Income Before Tax | -14.86% | -121.23% | -122.02% | 153.11% | -213.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.86% | -121.23% | -122.02% | 153.11% | -213.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.86% | -121.23% | -122.02% | 153.11% | -213.35% |
| EBIT | -10.46% | -5.50% | -12.19% | -86.90% | -186.68% |
| EBITDA | -11.77% | -6.51% | -13.34% | -98.60% | -201.96% |
| EPS Basic | 94.66% | 3.26% | 47.61% | -- | -548.72% |
| Normalized Basic EPS | 97.74% | -- | 53.81% | -- | -- |
| EPS Diluted | 94.66% | 3.26% | 47.61% | -- | -548.72% |
| Normalized Diluted EPS | 97.74% | -- | 53.81% | -- | -- |
| Average Basic Shares Outstanding | 5,000.40% | -- | 9,396.04% | -- | -- |
| Average Diluted Shares Outstanding | 5,000.40% | 1,187.86% | 9,396.04% | -- | -88.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |